Navigation Links
Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
Date:12/3/2008

l, Safe Anti-Thrombotic Strategy" (abstract # 409)

Monday, December 8, 11:00 AM

3002-3004 - West (Moscone Center)

"Inhibition of Syk Activity is Sufficient for Inhibitory Effect in Animal Models of Autoimmune Diseases" (abstract # 680)

    Monday, December 8, 5:15 PM
    2006-2008 - West (Moscone Center)

    Factor Xa Inhibitor Antidote

"Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors" (abstract # 983)

    Saturday, December 6, 5:30 PM
    Hall A (Moscone Center)

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concept that are engineered to provide significant advances over current treatments for cardiovascular and inflammatory diseases and cancer.

Portola's two lead Phase II compounds, betrixaban, an oral Factor Xa inhibitor and PRT060128, an ADP receptor antagonist, target the global multi- billion dollar antithrombotic market. Both product candidates have best-in- class features versus current and novel agents in development and address the hospital, specialty, and chronic care markets. The Company's earlier-stage programs are leveraging its chemistry capability to develop specific Syk and JAK inhibitors to treat cancer and inflammatory diseases. The company also has a novel Factor Xa inhibitor antidote program with the potential to help manage the more than 20 million patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit http://www.portola.com.

     Contact:
     Mardi Dier - CFO, Portola Pharmaceuticals
     650-246-7236
     mdier@portola.com

     Julie Normart, Invigorate Communications
     415-946-1087
     '/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
3. Novel Technology Breaks Through Cancer Pain
4. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
5. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
6. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
7. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
8. NIST team develops novel method for nanostructured polymer thin films
9. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Spartan Bioscience today announced that Paul Lem, ... the Ottawa Chamber of Commerce as one of the ... from over 240 applicants based on his business accomplishments, ... Dr. Lem founded Plexagen Diagnostics, and also served as ... Medical Degree from the University of Ottawa, and graduated ...
(Date:4/28/2015)... MA (PRWEB) April 28, 2015 ... (ACRES), a Massachusetts-based multi-stakeholder, non-profit organization dedicated to ... of a shared global system for clinical research, ... , an innovative new type of clinical research ... future of clinical research is changing,” said Greg ...
(Date:4/27/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the year ended December 31, 2014. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... not provide the outcome management and investors had ... iCo Therapeutics", said Andrew Rae , President ...
(Date:4/27/2015)... Dr. Robert Hanzlik, whose groundbreaking research ... implications for advancing the creation of safer pharmaceuticals, will ... University , the second-largest private, nonprofit university in California. ... professor at the University of Kansas School of Pharmacy ... at 5 p.m. and takes place at National University’s ...
Breaking Biology Technology:Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2ACRES Announces Innovative Clinical Research Event--SYNERGY 2ACRES Announces Innovative Clinical Research Event--SYNERGY 3ACRES Announces Innovative Clinical Research Event--SYNERGY 4iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3
... , , , Multiporator , , , , , , ... Transfection Protocol , Protocol No. 4308 915.046 11/2001 , , ... , , Cell line , ... Transfection with , pActin-SV-EGFP, ...
... , , , , , Multiporator , , , ... Transfection Protocol , Protocol No. 4308 915.020 11/1999 ... , , , , , , ... line), , , ...
... , , Multiporator / Electroporator 2510 , , , , , , ... Transformation Protocol , Protocol No. 4308 915.516 12/2001 , , ... , , , Microorganism , ... Cell type , Yeast, ...
Cached Biology Technology:L2 2Jurkat 2Jurkat 3Kluyveromyces lactis 2
(Date:4/20/2015)... -- Huntington Memorial Hospital is the first facility in ... wireless monitoring sensor to manage heart failure (HF). The ... heart failure monitoring device that has been proven to ... manage heart failure. The CardioMEMS HF System ... artery (PA) during a non-surgical procedure to directly measure ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... World Conservation Union reported an unprecedented decline in biodiversity, ... to most species is loss of habitat. And as ... to accurately predict the population dynamics and extinction risk ... a new study, John Drake tests models traditionally used ...
... genetic testing methods helped public health officials control and ... hepatitis A virus in 2003 related to the consumption ... in the October 15 issue of The Journal of ... the study, Joseph J. Amon, PhD, MSPH, and colleagues ...
... University of Barcelona, Spain, show for the first time ... the secondary fermentation of the sparkling wine known as ... General Meeting of the American Society for Microbiology. , ... impact upon sparkling wine quality in terms of aroma, ...
Cached Biology News:Traditional models underestimate extinction rates 2New tools used to control foodborne hepatitis A outbreaks related to green onions 2After the yeast is gone bacteria continue to develop flavor of sparkling wine 2
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... [HDAC8-48] to HDAC8 Regulation of ... mechanisms such as DNA methylation, ATP-dependent ... of histones, which include the dynamic ... of lysine residues present in the ...
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
Biology Products: